Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Adenocarcinoma of Lung 2 Uterine Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Radiomics 1 Prostatic Neoplasms 1 Pituitary Diseases 1 Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neuroendocrine Tumors 1 Lung Neoplasms 1 Lung Diseases 1 Liver Cirrhosis 1 Hepatitis B 1 Head and Neck Neoplasms 1 Disease Progression 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Lobular 1 Carcinoma, Ductal, Breast 1 Breast Neoplasms 1 Bone Neoplasms 1

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 9 Bevacizumab 8 toripalimab 7 senaparib 7 Fluorodeoxyglucose F18 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Fluorouracil 6 Gemcitabine 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor × Radiomics × Clear all

NCT04079283 2020-04-02

RIREP

Tianjin Medical University Cancer Institute and Hospital

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡